Frontiers Association of Lipoprotein(a)-Associated Mortality and

Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention

Full article: A Non-Linear Association of High-Density Lipoprotein Cholesterol with All-Cause and Cause-Specific Mortality in Diabetic Patients

Molecules, Free Full-Text

Frontiers Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages

Frontiers The Associations of Lipid Profiles With Cardiovascular Diseases and Death in a 10-Year Prospective Cohort Study

Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks – Consult QD

Association of Lipoprotein(a) With Atherosclerotic Plaque Progression

Frontiers Association of Lipoprotein(a)-Associated Mortality and the Estimated Glomerular Filtration Rate Level in Patients Undergoing Coronary Angiography: A 51,500 Cohort Study

A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies - ScienceDirect

Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease - Atherosclerosis

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

Frontiers Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study

Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry - Berman - 2020 - Clinical Cardiology - Wiley Online Library

Lp(a) and CVD Risk: Essential Knowledge for Clinicians with Treatment